[{"address1": "4224 Campus Point Court", "address2": "Suite 210", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 202 6300", "website": "https://www.regulusrx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.", "fullTimeEmployees": 31, "companyOfficers": [{"maxAge": 1, "name": "Mr. Joseph P. Hagan M.B.A.", "age": 54, "title": "CEO & Director", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 958232, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Crispina  Calsada CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 579300, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Ray Aker J.D.", "age": 62, "title": "Senior VP, General Counsel & Corporate Secretary", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 575942, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preston S. Klassen M.D., M.H.S.", "age": 54, "title": "President, Head of Research & Development and Director", "yearBorn": 1969, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Daniel J. Penksa", "age": 37, "title": "VP of Finance & Controller", "yearBorn": 1986, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Claire Susan Padgett M.S., M.T., Ph.D.", "title": "Senior Vice President of Clinical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rekha  Garg M.D., M.S.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Lee Ph.D.", "title": "Vice President of Translational Medicine", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.58, "open": 1.56, "dayLow": 1.5211, "dayHigh": 1.68, "regularMarketPreviousClose": 1.58, "regularMarketOpen": 1.56, "regularMarketDayLow": 1.5211, "regularMarketDayHigh": 1.68, "beta": 1.622, "forwardPE": -1.6868687, "volume": 1048975, "regularMarketVolume": 1048975, "averageVolume": 382401, "averageVolume10days": 485910, "averageDailyVolume10Day": 485910, "bid": 1.62, "ask": 1.67, "bidSize": 100, "askSize": 400, "marketCap": 109328048, "fiftyTwoWeekLow": 1.08, "fiftyTwoWeekHigh": 3.79, "fiftyDayAverage": 1.6266, "twoHundredDayAverage": 1.83865, "currency": "USD", "enterpriseValue": 16295013, "floatShares": 42378026, "sharesOutstanding": 65465900, "sharesShort": 3292534, "sharesShortPriorMonth": 3575878, "sharesShortPreviousMonthDate": 1723680000, "dateShortInterest": 1726185600, "sharesPercentSharesOut": 0.050300002, "heldPercentInsiders": 0.016900001, "heldPercentInstitutions": 0.9546, "shortRatio": 11.75, "shortPercentOfFloat": 0.0639, "impliedSharesOutstanding": 65465900, "bookValue": 1.5, "priceToBook": 1.1133333, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -35390000, "trailingEps": -1.2, "forwardEps": -0.99, "pegRatio": -0.05, "lastSplitFactor": "1:10", "lastSplitDate": 1656460800, "enterpriseToEbitda": -0.438, "52WeekChange": 0.2014389, "SandP52WeekChange": 0.34083736, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "RGLS", "underlyingSymbol": "RGLS", "shortName": "Regulus Therapeutics Inc.", "longName": "Regulus Therapeutics Inc.", "firstTradeDateEpochUtc": 1349789400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cd43addf-be3b-3da4-8113-29f5cb221300", "messageBoardId": "finmb_36742485", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.67, "targetHighPrice": 28.0, "targetLowPrice": 3.0, "targetMeanPrice": 10.33, "targetMedianPrice": 7.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 94460000, "totalCashPerShare": 1.443, "ebitda": -37208000, "totalDebt": 1422000, "quickRatio": 17.948, "currentRatio": 19.065, "debtToEquity": 1.448, "returnOnAssets": -0.31731, "returnOnEquity": -0.53549, "freeCashflow": -20038500, "operatingCashflow": -32781000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-03"}]